Rob Moormann

Prof. Dr. Rob Moormann received his PhD from the Catholic University of Nijmegen, The Netherlands in 1983 and then spend most of his scientific career at the CVI in Lelystad. His major achievements in vaccinology include the development of vaccines that can be used to “Differentiate Infected from Vaccinated Animals” (DIVA)

Rift Valley fever virus vaccine development

He participated in the development of a DIVA vaccine for Aujesky’s disease (AD) which was used to eradicate this disease in The Netherlands in the 1990’s, also in the 1990s, a DIVA vaccine for Classical swine fever virus was developed and brought to the market. In 1991, he was part of group of scientists that discovered the Porcine Reproductive and Respiratory Syndrome virus (PRRSV), a virus still causing huge economic losses in the swine industry worldwide. Apart from developing new vaccines and vaccination strategies, he was also involved in strategic decision making and choices for research topics in this field on the National and European level. Through these activities, vector borne zoonotic bunyaviruses like Rift Valley fever virus (RVFV) and Crimean-Congo Hemorrhagic fever virus (CCHFV) became recognized as emerging threats to the Western European society. In 2007 he was appointed as a part time professor in Vaccinology, with a special focus on viral vector borne zoonotic diseases like RVFV and CCHFV, at the Department of Virology of the Faculty of Animal Health of the University of Utrecht (UU).